| Literature DB >> 33271378 |
Kwadwo Sarpong1, Ehsan Dowlati2, Charles Withington1, Kelsi Chesney3, William Mualem1, Kathryn Hay1, Tianzan Zhou3, Jordan Black1, Matthew Shashaty1, Christopher G Kalhorn3, Mani N Nair3, Daniel R Felbaum4.
Abstract
OBJECTIVE: Coronavirus disease 2019 (COVID-19) continues to affect all aspects of health care delivery, and neurosurgical practices are not immune to its impact. We aimed to evaluate neurosurgical practice patterns as well as the perioperative incidence of COVID-19 in neurosurgical patients and their outcomes.Entities:
Keywords: COVID-19; Neurointerventional; Neurosurgery; Nosocomial infection; Pandemic response; SARS-CoV-2
Mesh:
Year: 2020 PMID: 33271378 PMCID: PMC7703227 DOI: 10.1016/j.wneu.2020.11.133
Source DB: PubMed Journal: World Neurosurg ISSN: 1878-8750 Impact factor: 2.104
Figure 1Timeline of coronavirus disease 2019 (COVID-19) pandemic with portrayal of study timeline starting March 8, 2020 (coinciding with the first COVID-19 diagnosis in Washington, DC) and divided into peak-pandemic period (March 8-June 8) and post-peak pandemic period (June 9-Sept 9). In-patient census of COVID-19–positive patients at 2 tertiary care centers in Washington, DC, shown as line graph with peak on April 30, 2020. Elective cases were cancelled starting March 18, 2020, and resumed for neurosurgery on June 1, 2020, along with Phase I of DC reopening.
Figure 2(A) Surgical operative case volume and (B) neurointerventional case volume compared between 2020 peak pandemic period to the following post-peak pandemic period. There was a significant increase in number of weekly case volumes for both surgical (P = 0.0012) and neurointerventional (P = 0.0002) cases.
Baseline Characteristics and Outcomes of Patients Undergoing Neurosurgical Procedures During Peak Pandemic (March 8 to June 8) and Post-Peak Pandemic Period (June 9 to September 9)
| March 8 to June 8 | June 9 to September 9 | ||
|---|---|---|---|
| Total cases | 405 | 652 | 0.0002 |
| Total patients | 386 | 610 | 0.0002 |
| Mean age, years | 57.1 ± 16.2 | 57.8 ± 14.2 | 0.4668 |
| Male sex | 207 (53.6) | 300 (49.2) | 0.1728 |
| Preoperative tests | 231 (57.0) | 652 (100.0) | <0.0001 |
| Mean days tested preoperative | 2.3 ± 3.1 | 2.7 ± 1.5 | 0.0367 |
| Preoperative negative | 225 (97.4) | 639 (98.0) | 0.6004 |
| Preoperative positive | 6 (2.6) | 13 (2.0) | |
| Postoperative tests | 115 (28.4) | 225 (34.5) | 0.0422 |
| Mean days tested postoperative | 11.6 ± 10.3 | 11.4 ± 8.7 | 0.7385 |
| Postoperative negative | 111 (96.5) | 218 (96.9) | 0.9999 |
| Postoperative positive | 4 (3.5) | 7 (3.1) | |
| Case acuity | <0.0001∗ | ||
| Emergent | 92 (22.7) | 60 (9.2) | <0.0001 |
| Urgent | 183 (45.2) | 114 (17.5) | <0.0001 |
| Elective | 123 (30.4) | 478 (73.3) | <0.0001 |
| Case type | 0.0005 | ||
| Spine—cervical/cervicothoracic | 85 (21.0) | 120 (18.4) | 0.3370 |
| Spine—thoracic | 32 (7.9) | 27 (4.1) | 0.0526 |
| Spine—lumbar/thoracolumbar | 105 (25.9) | 214 (33.0) | 0.0191 |
| Craniotomy—tumor/abscess | 53 (13.0) | 73 (11.2) | 0.3800 |
| Craniotomy—vascular lesions | 25 (6.2) | 27 (4.1) | 0.1454 |
| Craniotomy—ICH/CVA/trauma | 32 (7.9) | 50 (7.7) | 0.9062 |
| Functional/pain | 23 (5.7) | 60 (9.0) | 0.0451 |
| CSF diversion | 20 (4.9) | 25 (3.8) | 0.4341 |
| Endonasal/transsphenoidal | 19 (4.7) | 23 (3.5) | 0.4182 |
| Cranioplasty | 0 (0.0) | 19 (2.9) | 0.0001 |
| Other | 9 (2.2) | 14 (2.1) | 0.9999 |
| Race/ethnicity | 0.8544 | ||
| White Non-Hispanic | 203 (52.6) | 301 (49.3) | 0.3297 |
| Black/African-American | 139 (36.0) | 236 (38.7) | 0.4207 |
| Hispanic | 22 (5.7) | 39 (6.4) | 0.6866 |
| Asian | 9 (2.3) | 16 (2.6) | 0.8381 |
| Other | 13 (3.4) | 18 (3.0) | 0.7117 |
| Comorbidities | 0.9109 | ||
| HTN | 190 (49.2) | 326 (53.4) | 0.2162 |
| DM | 76 (19.7) | 133 (21.8) | 0.4724 |
| CAD | 28 (7.3) | 66 (10.8) | 0.0746 |
| CKD/ESRD | 20 (5.2) | 44 (7.2) | 0.2333 |
| Malignancy | 50 (13.0) | 88 (14.4) | 0.5724 |
| COPD | 11 (2.8) | 24 (3.9) | 0.4803 |
| DVT/PE | 20 (5.2) | 35 (5.7) | 0.7768 |
| CVA/TIA | 25 (6.5) | 49 (8.0) | 0.3877 |
| Mean mMeNTS score | 8.2 ± 1.6 | 7.5 ± 1.3 | <0.0001 |
| Median ASA status [IQR] | 3 [2–4] | 3 [2–4] | 0.0749 |
| Mean LOS | 8.9 ± 11.0 | 8.1 ± 12.2 | 0.2901 |
| Complications | 77 (19.0) | 82 (12.6) | 0.0059 |
| 30-day readmission | 32 (7.9) | 64 (9.8) | 0.3227 |
| Disposition | 0.2736 | ||
| Home | 285 (70.4) | 497 (76.2) | 0.0367 |
| Death/hospice | 17 (4.2) | 19 (2.9) | 0.2965 |
| Acute rehabilitation | 68 (16.8) | 89 (13.7) | 0.1820 |
| Skilled nursing facility | 27 (6.7) | 39 (6.0) | 0.6955 |
| Long-term care facility | 8 (2.0) | 8 (1.2) | 0.4376 |
ICH, intracranial hemorrhage; CSF, cerebrospinal fluid; HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis; PE, pulmonary embolism; CVA, cerebrovascular accident; TIA, transient ischemic attack; mMeNTS, modified Medically-Necessary, Time-Sensitive Procedures; ASA, American Society of Anesthesiologists; IQR, interquartile range; LOS, length of stay.
Statistically significant.
Baseline Characteristics and Outcomes of Patients Undergoing Neurointerventional Procedures During Peak Pandemic (March 8 to June 8) and Post-Peak Pandemic Period (June 9 to September 9)
| March 8 to June 8 | June 9 to September 9 | ||
|---|---|---|---|
| Total cases | 121 | 217 | 0.0012 |
| Total patients | 112 | 180 | 0.0009 |
| Mean age, years | 61.3 ± 15.4 | 59.2 ± 14.7 | 0.2167 |
| Male sex | 65 (58.0) | 83 (46.1) | 0.0544 |
| Preoperative tests | 88 (72.7) | 217 (100.0) | <0.0001 |
| Mean days tested preoperative | 1.5 ± 2.3 | 1.9 ± 2.1 | 0.1057 |
| Preoperative negative | 81 (92.0) | 208 (95.9) | 0.2542 |
| Preoperative positive | 7 (8.0) | 9 (4.1) | |
| Postoperative tests | 64 (52.9) | 138 (63.6) | 0.0642 |
| Mean days tested Postoperative | 11.1 ± 8.8 | 9.6 ± 7.1 | 0.2293 |
| Postoperative negative | 63 (98.4) | 132 (95.7) | 0.4354 |
| Postoperative positive | 1 (1.6) | 6 (4.3) | |
| Case acuity | <0.0001 | ||
| Emergent | 70 (57.9) | 78 (34.6) | 0.0002 |
| Urgent | 34 (28.1) | 74 (34.1) | 0.2754 |
| Elective | 16 (13.2) | 65 (31.3) | 0.0005 |
| Case type | 0.0414 | ||
| Diagnostic cerebral | 39 (32.2) | 103 (47.5) | 0.0081 |
| Embolization—aneurysm/AVM | 21 (17.4) | 31 (14.3) | 0.3406 |
| Embolization—tumor | 6 (5.0) | 9 (4.1) | 0.5784 |
| Embolization—MMA | 11 (9.1) | 17 (7.8) | 0.8386 |
| Stroke thrombectomy | 29 (24.0) | 30 (13.8) | 0.1080 |
| Vasospasm treatment | 6 (5.0) | 14 (6.5) | 0.6403 |
| Spine intervention | 8 (6.6) | 6 (2.8) | 0.1514 |
| Carotid stent | 4 (3.3) | 6 (2.8) | 0.7496 |
| Other | 5 (4.1) | 1 (0.5) | 0.1025 |
| Race/ethnicity | 0.2516 | ||
| White Non-Hispanic | 58 (51.8) | 72 (40.0) | 0.0534 |
| Black/African-American | 45 (40.2) | 81 (45.0) | 0.4665 |
| Hispanic | 3 (2.7) | 10 (5.6) | 0.3825 |
| Asian | 2 (1.8) | 7 (3.9) | 0.4902 |
| Other | 4 (3.6) | 9 (5.0) | 0.5775 |
| Comorbidities | 0.7805 | ||
| HTN | 76 (67.9) | 97 (54.0) | 0.0567 |
| DM | 26 (23.2) | 45 (25.0) | 0.7294 |
| CAD | 15 (13.4) | 13 (7.2) | 0.0816 |
| CKD/ESRD | 12 (10.7) | 14 (8.0) | 0.4048 |
| Malignancy | 18 (16.1) | 19 (11.0) | 0.2054 |
| COPD | 8 (7.2) | 10 (5.6) | 0.6217 |
| DVT/PE | 5 (4.5) | 6 (3.3) | 0.7539 |
| CVA/TIA | 5 (4.5) | 11 (6.0) | 0.6083 |
| Mean mMeNTS score | 9.0 ± 1.8 | 7.8 ± 1.5 | <0.0001 |
| Median ASA status [IQR] | 3 [2–4] | 3 [2–4] | 0.9999 |
| Mean LOS | 13.5 ± 10.8 | 14.9 ± 13.3 | 0.3229 |
| Complications | 58 (47.9) | 51 (23.5) | <0.0001 |
| 30-day readmission | 7 (5.8) | 19 (8.8) | 0.3979 |
| Disposition | 0.0896 | ||
| Home | 49 (40.5) | 112 (51.6) | 0.0498 |
| Acute rehabilitation | 48 (39.7) | 70 (32.3) | 0.1910 |
| Skilled nursing facility | 12 (9.9) | 10 (4.6) | 0.0675 |
| Long-term care facility | 1 (0.8) | 6 (2.8) | 0.4287 |
| Death/hospice | 11 (9.1) | 21 (9.7) | 0.9999 |
AVM, arteriovenous malformation; MMA, middle meningeal artery; HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis; PE, pulmonary embolism; CVA, cerebrovascular accident; TIA, transient ischemic attack; mMeNTS, modified Medically-Necessary, Time-Sensitive Procedures; ASA, American Society of Anesthesiologists; IQR, interquartile range; LOS, length of stay.
Statistically significant.
Figure 3(A) Surgical case volume by case type comparing peak pandemic period with post-peak pandemic period. (B) Surgical cases over time during peak pandemic period and post-peak pandemic period divided into spinal (solid lines) and cranial (dotted lines) cases. (C) Neurointerventional case volume by case type comparing peak pandemic period with post-peak pandemic period.
Differences Between COVID-19–Positive and–Negative Patients Undergoing Neurosurgical and Neurointerventional Procedures During the Post-Peak Pandemic Period (June 9 to September 9)
| COVID-19 (+) | COVID-19 (–) | ||
|---|---|---|---|
| Total tests | 35 | 1197 | |
| Total cases | 33 | 836 | |
| Total patients | 28 | 762 | |
| Case category | |||
| Surgical | 20 (57.1) | 634 (75.8) | 0.0165 |
| Neurointerventional | 15 (42.9) | 202 (24.2) | |
| Positive preoperative | 22 (62.9) | ||
| Positive postoperative | 13 (37.1) | ||
| Total negative preoperative | 847 (70.8) | ||
| Total negative postoperative | 350 (29.2) | ||
| Mean age, years | 51.1 ± 14.5 | 58.4 ± 14.3 | 0.0054 |
| Male sex | 18 (64.3) | 375 (49.2) | 0.1172 |
| Case acuity | <0.0001 | ||
| Emergent | 15 (45.5) | 119 (14.2) | <0.0001 |
| Urgent | 13 (39.4) | 147 (17.6) | 0.0044∗ |
| Elective | 5 (15.1) | 570 (68.2) | <0.0001 |
| Case type | 0.1057 | ||
| Spine—cervical/cervicothoracic | 3 (9.1) | 117 (14.0) | 0.6073 |
| Spine—thoracic | 1 (3.0) | 26 (3.1) | 0.9999 |
| Spine—lumbar/thoracolumbar | 4 (12.1) | 212 (25.4) | 0.1005 |
| Craniotomy—tumor/abscess | 2 (6.1) | 71 (8.5) | 0.9999 |
| Craniotomy—Vascular lesions | 2 (6.1) | 25 (3.0) | 0.2736 |
| Craniotomy—ICH/stroke/trauma | 4 (12.1) | 46 (5.5) | 0.1155 |
| Cranioplasty | 0 (0.0) | 18 (2.2) | 0.9999 |
| Functional/pain | 0 (0.0) | 59 (7.1) | 0.1601 |
| CSF diversion | 2 (6.1) | 23 (2.8) | 0.2447 |
| Endonasal/transsphenoidal | 0 (0.0) | 23 (2.8) | 0.9999 |
| Diagnostic cerebral | 8 (24.2) | 96 (11.5) | 0.0481 |
| Embolization—aneurysm/AVM | 3 (9.1) | 28 (3.3) | 0.1088 |
| Embolization—tumor | 0 (0.0) | 9 (1.1) | 0.9999 |
| Embolization—MMA | 0 (0.0) | 17 (2.0) | 0.9999 |
| Stroke thrombectomy | 2 (6.1) | 28 (3.3) | 0.3169 |
| Vasospasm treatment | 2 (6.1) | 12 (1.4) | 0.0957 |
| Spine intervention | 0 (0.0) | 6 (0.7) | 0.9999 |
| Carotid stent | 0 (0.0) | 6 (0.7) | 0.9999 |
| Other | 0 (0.0) | 14 (1.7) | 0.9999 |
| Race/ethnicity | <0.0001 | ||
| White Non-Hispanic | 7 (25.0) | 370 (48.6) | 0.0194 |
| African-American | 11 (39.3) | 306 (40.2) | 0.9999 |
| Hispanic | 10 (35.7) | 40 (5.2) | <0.0001 |
| Asian | 0 (0.0) | 18 (2.4) | 0.9999 |
| Other | 0 (0.0) | 28 (3.7) | 0.6186 |
| Comorbidities | 0.9994 | ||
| HTN | 16 (57.1) | 417 (54.7) | 0.8486 |
| DM | 7 (25.0) | 173 (22.7) | 0.8186 |
| CAD | 3 (10.7) | 76 (10.0) | 0.7536 |
| CKD/ESRD | 2 (7.1) | 58 (7.6) | 0.9999 |
| Malignancy | 3 (10.7) | 104 (13.6) | 0.9999 |
| COPD/asthma | 1 (3.6) | 33 (4.3) | 0.9999 |
| DVT/PE | 2 (7.1) | 39 (5.1) | 0.6519 |
| CVA/TIA | 2 (7.1) | 57 (7.5) | 0.9999 |
| Mean mMeNTS score | 9.0 ± 1.4 | 7.5 ± 1.4 | <0.0001 |
| Mean LOS | 27.5 ± 18.5 | 9.1 ± 9.6 | <0.0001 |
| Median ASA status [IQR] | 3 [2–4] | 4 [3–4] | <0.0001 |
| Complications | 19 (57.6) | 111 (13.3) | <0.0001 |
| 30-day readmission | 6 (18.2) | 80 (9.6) | 0.1042 |
| Disposition | <0.0001 | ||
| Home | 4 (12.1) | 604 (72.2) | <0.0001 |
| Death/hospice | 6 (18.2) | 34 (4.1) | 0.0029 |
| Acute rehabilitation | 14 (42.4) | 144 (17.2) | 0.0008 |
| Skilled nursing facility | 7 (21.2) | 41 (4.9) | 0.0014 |
| Long-term care facility | 2 (6.1) | 13 (1.6) | 0.1079 |
COVID-19, coronavirus disease 2019; ICH, intracranial hemorrhage; CSF, cerebrospinal fluid; AVM, arteriovenous malformation; MMA, middle meningeal artery; HTN, hypertension; DM, diabetes mellitus; CAD, coronary artery disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis; PE, pulmonary embolism; CVA, cerebrovascular accident; TIA, transient ischemic attack; mMeNTS, modified Medically-Necessary, Time-Sensitive Procedures; LOS, length of stay; ASA, American Society of Anesthesiologists; IQR, interquartile range.
Statistically significant.
Multivariate Logistic Regression for COVID-19–Positive Versus COVID-19–Negative Patients During the Post-Peak Pandemic Period
| Variable | OR | 95% CI | |
|---|---|---|---|
| Age <65 years | 7.027 | 2.503–24.76 | 0.0007 |
| Male sex | 2.174 | 0.935–5.366 | 0.0786 |
| Race/ethnicity | 0.6330 | 0.243–1.527 | 0.3252 |
| Nonelective case | 7.319 | 2.102–34.95 | 0.0044 |
| LOS >7 days | 5.669 | 1.502–21.98 | 0.0104 |
| ASA status | 0.7395 | 0.157–5.317 | 0.7243 |
| In-hospital complication | 2.617 | 1.108–6.370 | 0.0300 |
| Non-home disposition | 13.12 | 3.494–64.38 | 0.0005 |
| 30-day readmission | 1.983 | 0.637–5.697 | 0.2159 |
| mMeNTS score | 1.590 | 1.191–2.154 | 0.0020 |
COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; LOS, length of stay; ASA, American Society of Anesthesiologists; mMeNTS, modified Medically-Necessary, Time-Sensitive Procedures.
Statistically significant.
Figure 4(A) Proportion of race/ethnicity patients identify with in coronavirus disease 2019 (COVID-19) –positive versus–negative patients (P < 0.0001). (B) Proportion of elective, urgent, and emergent cases in COVID-19–positive versus–negative patients (P < 0.0001). (C) Proportion of disposition assignments of COVID-19–positive versus–negative patients (P < 0.0001). (D) Length of stay (LOS) of COVID-19––positive versus negative patients (mean shown with 95% CI) (27.5 vs. 9.1 days, P < 0.0001). (E) Modified Medically-Necessary, Time-Sensitive Procedures (mMeNTS) score for COVID-19–positive versus–negative patients (mean shown with 95% confidence interval) (9.0 vs. 7.5, P < 0.0001). ∗∗∗P < 0.0001.